Number of pages: 100 | Report Format: PDF | Published date: 17 November, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
The global respiratory disease imaging market was pegged at US$ 7.9 billion in 2021 and is expected to witness a CAGR of 8.4% during the forecast period.
Pneumology is the prevention, diagnosis, and treatment of disorders affecting the respiratory system. In addition to respiratory disorders, such as asthma and chronic obstructive pulmonary disorder, there is a range of other chronic conditions that can affect the lungs, e.g., cardiovascular disease, and cancer. Lung imaging approaches have provided health professionals with a better understanding of how the lung is affected by a range of disorders so treatments can be optimized. Imaging methods have helped researchers determine the precise nature of the underlying causes of many lung disorders, which has significantly improved pneumology diagnoses. Preclinical small animal imaging has provided valuable insights into the mechanisms of lung disease and the effects of treatment.
The primary factor fueling the market's expansion is the steadily rising incidence of respiratory diseases caused by rising air pollution levels. The market is being driven by the increase in air pollution and the discharge of dangerous gases that cause lung diseases like COPD and other respiratory illnesses all over the world. The expansion of illnesses like tuberculosis and hospital-acquired infections, when these tests are utilized as a preliminary detection tool, are among the major factors causing the total growth. Market acceptance of the use of technologically sophisticated tools, like pulse oximeters, for efficient management of COPD in outpatients is growing quickly.
However, limitations in reimbursement policies and the rising cost of healthcare are the major challenges for the global respiratory disease imaging market. Additionally, the lack of skilled professionals in healthcare setups is likely to slow down the market growth.
The global respiratory disease imaging market has been analyzed from three perspectives, type, disease indication, and region.
Respiratory Disease Imaging Market by Type
Based on type, the global respiratory disease imaging market has been subdivided into, X-ray, magnetic resonance imaging (MRI), computed tomography (CT) scan, nuclear imaging, and others. The market for imaging respiratory diseases worldwide is dominated by the X-ray segment. The category has expanded because of hospitals and diagnostic facilities using X-rays more frequently. X-rays are perfect for quick diagnosis and treatment plans because they are non-invasive, painless, and take less time. Chest x-rays are increasingly in demand as chest illnesses become more common.
Respiratory Disease Imaging Market by Disease Indication
Based on the disease indication, the global respiratory disease imaging market has been divided into chronic obstructive pulmonary disease, lung cancer, asthma, tuberculosis, and others. The chronic obstructive pulmonary disease segment dominates the respiratory disease imaging market. This is mainly attributed to its high prevalence globally.
Respiratory disease imaging Market by Region
Based on region, the global respiratory disease imaging market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. The market for imaging respiratory diseases was dominated by North America. The significant market share that North America has in the world can be linked to the region's growing geriatric and respiratory illness populations. A sophisticated healthcare system, reliable distribution channels for respiratory diagnostic devices, investments by major players in R&D, and the introduction of new products are other factors fostering the expansion of this market. During the projected period, it is anticipated that the U.S. will dominate the market in the North American region.
Some of the prominent players operating in the global respiratory disease imaging market are: -